GIP's involvement in the pathophysiology of type 2 diabetes

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Standard

GIP's involvement in the pathophysiology of type 2 diabetes. / Christensen, Mikkel B.; Gasbjerg, Lærke S.; Heimbürger, Sebastian M.; Stensen, Signe; Vilsbøll, Tina; Knop, Filip K.

I: Peptides, Bind 125, 170178, 03.2020.

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Harvard

Christensen, MB, Gasbjerg, LS, Heimbürger, SM, Stensen, S, Vilsbøll, T & Knop, FK 2020, 'GIP's involvement in the pathophysiology of type 2 diabetes', Peptides, bind 125, 170178. https://doi.org/10.1016/j.peptides.2019.170178

APA

Christensen, M. B., Gasbjerg, L. S., Heimbürger, S. M., Stensen, S., Vilsbøll, T., & Knop, F. K. (2020). GIP's involvement in the pathophysiology of type 2 diabetes. Peptides, 125, [170178]. https://doi.org/10.1016/j.peptides.2019.170178

Vancouver

Christensen MB, Gasbjerg LS, Heimbürger SM, Stensen S, Vilsbøll T, Knop FK. GIP's involvement in the pathophysiology of type 2 diabetes. Peptides. 2020 mar.;125. 170178. https://doi.org/10.1016/j.peptides.2019.170178

Author

Christensen, Mikkel B. ; Gasbjerg, Lærke S. ; Heimbürger, Sebastian M. ; Stensen, Signe ; Vilsbøll, Tina ; Knop, Filip K. / GIP's involvement in the pathophysiology of type 2 diabetes. I: Peptides. 2020 ; Bind 125.

Bibtex

@article{1fa3997902cd41b1bc6cc895e76d7cfc,
title = "GIP's involvement in the pathophysiology of type 2 diabetes",
abstract = "During the past four decades derangements in glucose-dependent insulinotropic polypeptide (GIP) biology has been viewed upon as contributing factors to various parts of the pathophysiology type 2 diabetes. This overview outlines and discusses the impaired insulin responses to GIP as well as the effect of GIP on glucagon secretion and the potential involvement of GIP in the obesity and bone disease associated with type 2 diabetes. As outlined in this review, it is unlikely that the impaired insulinotropic effect of GIP occurs as a primary event in the development of type 2 diabetes, but rather develops once the diabetic state is present and beta cells are unable to maintain normoglycemia. In various models, GIP has effects on glucagon secretion, bone and lipid homeostasis, but whether these effects contribute substantially to the pathophysiology of type 2 diabetes is at present controversial. The review also discusses the substantial uncertainty surrounding the translation of preclinical data relating to the GIP system and outline future research directions.",
keywords = "Entero-osseous axis, Gastric inhibitory peptide, GIP, Glucagon, Glucose-dependent insulinotropic polypeptide, Gut-bone axis, Incretin, Incretin effect, Insulin secretion, Obesity",
author = "Christensen, {Mikkel B.} and Gasbjerg, {L{\ae}rke S.} and Heimb{\"u}rger, {Sebastian M.} and Signe Stensen and Tina Vilsb{\o}ll and Knop, {Filip K.}",
year = "2020",
month = mar,
doi = "10.1016/j.peptides.2019.170178",
language = "English",
volume = "125",
journal = "Peptides",
issn = "0196-9781",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - GIP's involvement in the pathophysiology of type 2 diabetes

AU - Christensen, Mikkel B.

AU - Gasbjerg, Lærke S.

AU - Heimbürger, Sebastian M.

AU - Stensen, Signe

AU - Vilsbøll, Tina

AU - Knop, Filip K.

PY - 2020/3

Y1 - 2020/3

N2 - During the past four decades derangements in glucose-dependent insulinotropic polypeptide (GIP) biology has been viewed upon as contributing factors to various parts of the pathophysiology type 2 diabetes. This overview outlines and discusses the impaired insulin responses to GIP as well as the effect of GIP on glucagon secretion and the potential involvement of GIP in the obesity and bone disease associated with type 2 diabetes. As outlined in this review, it is unlikely that the impaired insulinotropic effect of GIP occurs as a primary event in the development of type 2 diabetes, but rather develops once the diabetic state is present and beta cells are unable to maintain normoglycemia. In various models, GIP has effects on glucagon secretion, bone and lipid homeostasis, but whether these effects contribute substantially to the pathophysiology of type 2 diabetes is at present controversial. The review also discusses the substantial uncertainty surrounding the translation of preclinical data relating to the GIP system and outline future research directions.

AB - During the past four decades derangements in glucose-dependent insulinotropic polypeptide (GIP) biology has been viewed upon as contributing factors to various parts of the pathophysiology type 2 diabetes. This overview outlines and discusses the impaired insulin responses to GIP as well as the effect of GIP on glucagon secretion and the potential involvement of GIP in the obesity and bone disease associated with type 2 diabetes. As outlined in this review, it is unlikely that the impaired insulinotropic effect of GIP occurs as a primary event in the development of type 2 diabetes, but rather develops once the diabetic state is present and beta cells are unable to maintain normoglycemia. In various models, GIP has effects on glucagon secretion, bone and lipid homeostasis, but whether these effects contribute substantially to the pathophysiology of type 2 diabetes is at present controversial. The review also discusses the substantial uncertainty surrounding the translation of preclinical data relating to the GIP system and outline future research directions.

KW - Entero-osseous axis

KW - Gastric inhibitory peptide

KW - GIP

KW - Glucagon

KW - Glucose-dependent insulinotropic polypeptide

KW - Gut-bone axis

KW - Incretin

KW - Incretin effect

KW - Insulin secretion

KW - Obesity

U2 - 10.1016/j.peptides.2019.170178

DO - 10.1016/j.peptides.2019.170178

M3 - Review

C2 - 31682875

AN - SCOPUS:85076992469

VL - 125

JO - Peptides

JF - Peptides

SN - 0196-9781

M1 - 170178

ER -

ID: 240313680